PRINT OUT

News Release 2018

November 08, 2018 Presentation Material for IR Meeting <PDF>
November 06, 2018 Outline of Consolidated Financial Results for the Second Quarter Ended September 30, 2018 <PDF>
October 17, 2018 New Drug Application Filed for defibrotide sodium <PDF>
October 03, 2018 NS-065/NCNP-01 (Viltolarsen) of Nippon Shinyaku’ in-house product Presentation on results of Phase I/II study in Japan <PDF>
October 03, 2018 NS-065/NCNP-01 (Viltolarsen) of Nippon Shinyaku’ in-house product Presentation on results of Phase II study in US/Canada <PDF>
September 19, 2018 Orphan drug designation granted to NS-73 <PDF>
August 29, 2018 Launch of the Anti-Cancer Agent / a Humanized Anti-CD20 Monoclonal Antibody “GAZYVA®" <PDF>
August 10, 2018 Presentations on NS-065/ NCNP-01 at the 23rd International Annual Congress of the World Muscle Society <PDF>
August 07, 2018 Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2018 <PDF>
August 07, 2018 Presentation Material for IR Meeting <PDF>
July 24, 2018 Nippon Shinyaku Supports Western Japan Heavy Rain Relief Efforts <HTML>
July 02, 2018 Humanized Anti-CD20 Monoclonal Antibody, “GAZYVA® Intravenous Infusion 1000 mg,” Approved for the Treatment of CD20-Positive Follicular Lymphoma <PDF>
June 28, 2018 Presentation of top line results of Phase I/II study of NS-065/NCNP-01 in Japan, for Duchenne muscular dystrophy <PDF>
June 28, 2018 Presentation of top line results of US/Canada Phase II study of NS-065/NCNP-01, for Duchenne muscular dystrophy <PDF>
June 01, 2018 Notice Of The 155th Annual General Meeting Of Shareholders <HTML>
May 11, 2018 Presentation Material for IR Meeting <PDF>
May 10, 2018 Presentations on NS-065/ NCNP-01 at 2018 New Directions in Biology and Disease of Skeletal Muscle Conference <PDF>
May 09, 2018 Outline of Consolidated Financial Results for the Year Ended March 31, 2018 <PDF>
April 19, 2018 Results of Exploratory Investigator-Initiated Clinical Trial of NS-065/NCNP-01 <PDF>
February 06, 2018 Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2017 <PDF>
February 06, 2018 Presentation Material for IR Meeting <PDF>
get_adobe_reader
page-top